Debt-hobbled Glenmark is looking to boost earnings. Execution will be key to winning back investors.

Glenn Saldanha, managing director and CEO, Glenmark pharmaceuticals; image credit: Agencies


Coping with a tough US generics business and high R&D spends, Glenmark’s earnings growth has been muted. To realign with the changing business environment, the company has set new goals for the next four-five years, which includes doubling down on India, its stronghold. What’s will the company need to achieve its new targets and reclaim investor confidence?

Six years ago, Glenmark Pharmaceuticals had come out with a blueprint of its growth plan for the next decade. The key theme was to transition from a being a pure-play generics player to a company with an optimal mix of generics, specialty, and research-driven innovative products. The growth plan was largely centred on the US market. The company had then said that by FY25, 30% of its total revenue would come from specialty and innovative

  • SAVE

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

Leave a Reply

Your email address will not be published. Required fields are marked *